NCT07129902 Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department
| NCT ID | NCT07129902 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Vermont |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-09-02 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Project Summary The goal of this pilot clinical trial is to assess contingency management (CM) for increasing attendance at outpatient clinics after Medication for Opioid Use Disorder (MOUD) prescription and clinic referral occurred in the hospital Emergency Department (ED). * The researchers will compare usual care (UC)+CM to UC alone to see if 1) CM works to promote MOUD clinic attendance after discharge from the ED and 2) demonstrate feasibility of providing CM in the ED and outpatient MOUD clinic settings. * Researchers will randomize 30 adults who started MOUD in the ED into two conditions. These conditions consist of (A) UC alone: A referral to an outpatient buprenorphine or methadone provider with reminders from STAR program staff or (B) UC+CM: UC plus financial incentives dependent on MOUD clinic attendance to receive an MOUD prescription. The primary outcome of interest is the number of participants who receive their first MOUD prescription from the outpatient clinic after discharge from the ED in UC+CM compared to the UC-only condition. A secondary outcome will be the proportion of participants who kept attending outpatient MOUD treatment by the end of the 30-day study period between UC+CM and UC conditions. An exploratory outcome will be biochemically-verified illicit opioid abstinence measured at day 30.
Eligibility Criteria
Major inclusion criteria include * STAR referral to outpatient clinic (Addiction Treatment Center and Chittenden Clinic) with prescription for buprenorphine or methadone. * Age ≥18 years. * Provide informed consent. Exclusion Criteria * Pending incarceration in the next 30 days. * Plan to leave the area (Burlington/Chittenden County) in the next 30 days. * Physical, health, or structural challenge that prevents attendance at outpatient clinic.
Contact & Investigator
Eric A Thrailkill, Ph.D.
PRINCIPAL INVESTIGATOR
University of Vermont
Frequently Asked Questions
Who can join the NCT07129902 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07129902 currently recruiting?
Yes, NCT07129902 is actively recruiting participants. Contact the research team at eric.thrailkill@uvm.edu for enrollment information.
Where is the NCT07129902 trial being conducted?
This trial is being conducted at Burlington, United States.
Who is sponsoring the NCT07129902 clinical trial?
NCT07129902 is sponsored by University of Vermont. The principal investigator is Eric A Thrailkill, Ph.D. at University of Vermont. The trial plans to enroll 30 participants.